Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | CGAS | Q8N884 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.43 |
| ▸ | USP7 | Q93009 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7375246 | 0.91 | ALDH1A1 (0.54) | NPC1RAB9ACGASKDM4EALDH1A1 | |
| SCHEMBL7372857 | 0.89 | MAPT (0.41) | NPC1RAB9ACGASALOX5KDM4E | |
| SCHEMBL3382655 | 0.81 | KDM4E (0.53) | NPC1RAB9AALOX5KDM4EALDH1A1 | |
| SCHEMBL9571764 | 0.77 | RAB9A (0.68) | NPC1RAB9ACGASKDM4EALDH1A1 | |
| SCHEMBL7235014 | 0.75 | RAB9A (0.53) | NPC1RAB9ACGASALOX5KDM4E | |
| SCHEMBL7505250 | 0.74 | LMNA (0.38) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL27498721 | 0.74 | LMNA (0.38) | NPC1RAB9AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL12056713 | 0.73 | ALOX5 (0.54) | NPC1RAB9ACGASALOX5KDM4E | |
| SCHEMBL1691295 | 0.72 | SMN1; SMN2 (0.51) | NPC1RAB9ACGASALOX5KDM4E | |
| SCHEMBL5630676 | 0.72 | GABRA1 (0.72) | NPC1RAB9ACGASKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | NEUROGEN CORPORATION | 2002-03-14 | — | — | US | claimed |
| WO-2002002557-A2 | 2-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES: A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-10 | — | — | WO | claimed |
| US-6552037-B2 | An imidazo(1,2-a)Pyridine compound useful for altering the signal-transducing activity of gamma-aminobuytric acid receptor | NEUROGEN CORPORATION | 2003-04-22 | — | — | US | disclosed |
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | NEUROGEN CORPORATION | 2002-03-14 | — | — | US | disclosed |
| WO-2002002557-A2 | 2-PHENYLIMIDAZO[1,2-A]PYRIDINE DERIVATIVES: A NEW CLASS OF GABA BRAIN RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032200-A1 | 2-Substituted imidazo[1,2-A]pyridine derivatives | GABBR2, GABRP, GABBR1 | NPC1 941/4885RAB9A 2092/4885CGAS 3000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.